Safety Profile of the Fluoroquinolones

@article{Liu2010SafetyPO,
  title={Safety Profile of the Fluoroquinolones},
  author={Hans H. Liu},
  journal={Drug Safety},
  year={2010},
  volume={33},
  pages={353-369}
}
The fluoroquinolone class of antibacterial agents are among the most frequently prescribed drugs, with utility in a broad range of bacterial infections. Although very useful agents, the fluoroquinolones as a class are associated with a number of adverse events, some with considerable clinical significance. In the past 15–20 years, tolerability concerns have led to restrictions on the use of the fluoroquinolones and, in some instances, the withdrawal of agents from the market.This review focuses… Expand
Risks associated with the therapeutic use of fluoroquinolones
Introduction: Quinolones are among the most often prescribed antimicrobial agents. Some types of toxicity observed during therapy with these drugs have gained much attention. Areas covered: Here, weExpand
The Safety of Levofloxacin in Tuberculosis Treatment Including Drug-induced Hepatotoxicity
Introduction The fluoroquinolone class of antibacterial agents is one of most prescribed in the world (1). Some quinolones, such as ciprofloxacin, levofloxacin, moxifloxacin and gemifloxacin, areExpand
Levofloxacin-Associated Mania: A Case Report.
TLDR
A middle-aged woman treated with levofloxacin after cholecystectomy, who developed mania that resolved after specific treatment with risperidone and lorazepam is reported, suggestive of possible diagnosis of levoquinolones-induced mania. Expand
Fluoroquinolones in Community-Acquired Pneumonia
TLDR
Fluoroquinolone monotherapy may be associated with shorter hospital length of stay compared with β-lactam plus macrolide combination therapy, particularly in severe pneumonia or with high-dose therapy, and may have a role in healthcare-associated pneumonia when administered in combination with other antipseudomonal and anti-methicillin-resistant Staphylococcus aureus therapies. Expand
Cutaneous Adverse Reactions to Fluoroquinolones
TLDR
It is suggested that individual fluoroquinolones are responsible for different types and frequencies of cutaneous reactions, with some potentiality of cross‐reactivity between different generations. Expand
Fluoroquinolones for the treatment of tuberculosis in children.
TLDR
Although there is limited paediatric safety data for the prolonged treatment of MDR-TB, extended administration of fluoroquinolones in adults with M DR-TB does not show serious adverse effects and there is no evidence suggesting less tolerability of fluorosquinolone in children. Expand
Hepatic safety of antibiotics used in primary care
TLDR
Patients at risk are mainly those with previous experience of hepatotoxic reaction to antibiotics, the aged or those with impaired hepatic function in the absence of close monitoring, making it important to carefully balance potential risks with expected benefits in primary care. Expand
Adverse Effects of Fluoroquinolones: A Retrospective Cohort Study in a South Indian Tertiary Healthcare Facility
TLDR
A harmful association between FQ use and the development of ADRs is concluded, and FQs are not safe compared to other antibiotics, Hence, the use of F Qs should be limited to the conditions where no other alternatives are available. Expand
Safety and Tolerability Profile of Second-Line Anti-Tuberculosis Medications
TLDR
Safety and tolerability information regarding second-line anti-TB drugs in both adults and children is compiled and routinely monitored to prevent adverse drug reactions. Expand
Fluoroquinolones Reported Hepatotoxicity
TLDR
Most clinically used fluoroquinolones are relatively safe but Clinicians should consider patients liver function status before fluoroquolones clinical recommendation and in some cases biochemical parameters associated with liver function should be monitored in patients with impaired liver function. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 105 REFERENCES
Safety of fluoroquinolones: An update.
  • L. Mandell, G. Tillotson
  • Medicine
  • The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses
  • 2002
TLDR
New introduced fluoroquinolones, such as moxifloxacin and gatiflOxacin, are examined in terms of anticipated class effects and recent clinical experience. Expand
Safety Considerations of Fluoroquinolones in the Elderly
TLDR
Overall, the specific adverse-effect profile of quinolones must be considered when they are chosen for treatment of bacterial infections because of physiological changes in renal function and when certain co-morbidities are present, some special considerations are necessary when elderly patients are treated with these drugs. Expand
Comparative Tolerability of the Newer Fluoroquinolone Antibacterials
TLDR
Among the newer fluoroquinolones, clinically significant cardiac events are rare or absent but possible interactions in patients receiving other drugs capable of causing QT prolongation should be anticipated. Expand
Efficacy and safety of levofloxacin in the context of other contemporary fluoroquinolones: a review.
  • P. Ball
  • Medicine
  • Current therapeutic research, clinical and experimental
  • 2003
TLDR
Levofloxacin offers a combination of documented efficacy and tolerability, and provides an important option for the treatment of bacterial infections, including CAP and AECB, compared with standard agents used in the management of lower respiratory tract infections. Expand
Antimicrobial safety: focus on fluoroquinolones.
  • R. Owens, P. Ambrose
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2005
TLDR
The currently marketed quinolones are well tolerated, with safety profiles similar to those of other antimicrobial classes, although adverse effects are unusual, some, including tendinitis and CNS-related effects, are more common with quInolones than with other antimacterial classes. Expand
Safety Profile of the Respiratory Fluoroquinolone Moxifloxacin
TLDR
The data show that using moxifloxacin, in its accepted indications and following the corresponding guidelines, should not be associated with an excessive incidence of drug-related adverse reactions, provided the clinician takes care in identifying patients with known risk factors and pays due attention to the contraindications and warnings mentioned in the labelling. Expand
Infectious Diseases: Safety Concerns with Fluoroquinolones
TLDR
Clinicians should be aware of possible alterations in blood glucose, QTc interval prolongation, seizures, phototoxicity, tendinopathy, or CDAD with the use of any fluoroquinolone, especially in patients with other risk factors for these conditions. Expand
The Use of Systemic Fluoroquinolones
TLDR
Fluoroquinolone use should be restricted to situations in which there is no safe and effective alternative to treat an infection caused by multidrug-resistant bacteria or to provide oral therapy when parenteral therapy is not feasible and no other effective oral agent is available. Expand
Clinical use of the fluoroquinolones.
TLDR
With the immediate abundance of quinolones available for use, the safest, most effective, and best-tolerated agents will likely emerge as the most appropriate therapeutic choices when a quInolone is indicated. Expand
Fluoroquinolone toxicity profiles: a review focusing on newer agents.
  • Benjamin A Lipsky, C. Baker
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1999
TLDR
Fluoroquinolones are safe in elderly, human immunodeficiency virus-infected, and neutropenic patients, but because of possible effects on articular cartilage, they are not currently recommended for children or pregnant women. Expand
...
1
2
3
4
5
...